Sarcoma  >>  Imfinzi (durvalumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

19 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imfinzi (durvalumab) / AstraZeneca
ESR-16-12012, NCT06446570: Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Completed
2
18
RoW
Durvalumab,Tremelimumab, Experimental group
Seoul National University Hospital, Korean Cancer Study Group
HNSCC, Head and Neck Neoplasms
02/19
06/21
NCT03022500: Pulmonary sarcomatoid_MEDI4736+Treme

Completed
2
32
RoW
durvalumab + tremelimumab
Seoul National University Hospital
Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
02/18
11/19
NCT02423863: In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Completed
2
26
US
Hiltonol, Poly-ICLC, Nivolumab, Pembrolizumab, Atezolizumab, Cemiplimab, Durvalumab
Oncovir, Inc., National Institutes of Health (NIH), Icahn School of Medicine at Mount Sinai, Bay Hematology Oncology, National Cancer Institute (NCI), University of Missouri-Columbia, Chevy Chase Regional Cancer Care Associates LLC, Dermatologic Surgery Center of Washington LLC and Skin Cancer Treatment Center
Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
08/20
08/20
NCT04224337: Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma

Active, not recruiting
2
34
RoW
Durvalumab + doxorubicin + ifosfamide
Seoul National University Hospital
Carcinoma, Non-Small-Cell Lung
08/23
05/25
NCT02879162: Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Active, not recruiting
2
140
Canada
Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Advanced Rare Tumours
06/22
12/22
NCT03798106: A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Completed
2
46
RoW
Durvalumab, pazopanib
Yonsei University
Sarcoma
08/22
08/22
NCT03912818: Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Terminated
2
7
US
Carboplatin, Carboplat, Carboplatino, Carbosol, Paraplatin, Paraplatine, Cisplatin, Abiplatin, Briplatin, Cis-platinum, Cismaplat, Citoplatino, Plastistil, Platinol, Cystectomy, Doxorubicin, Adriablastin, Hydroxyl Daunorubicin, Rubex, Durvalumab, Imfinzi, MEDI-4736, Gemcitabine, Difluorodeoxycytidine, Gemzar, Methotrexate, Abitrexate, Amethopterin, Brimexate, Methotrexate Methylaminopterin, Metotrexato, Vinblastine, Vincaleucoblastine, Vinblastine Sulfate, vincaleukoblastine, sulfate
Stanford University, AstraZeneca
Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
08/22
08/22
MEDISARC, NCT03317457 / 2016-004750-15: Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Completed
2
103
Europe
Durvalumab and Tremelimumab, Doxorubicin
AIO-Studien-gGmbH, AstraZeneca
Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
08/22
08/22
NCT03015129: A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Completed
2
80
US
Durvalumab, Tremelimumab
Memorial Sloan Kettering Cancer Center
Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent, Endometrial Carcinoma, Recurrent
12/22
12/22
CAIRE, NCT04705818: Combining Epigenetic And Immune Therapy to Beat Cancer.

Recruiting
2
173
Europe
Durvalumab, Tazemetostat
Institut Bergonié, AstraZeneca, Epizyme, Inc.
Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma, Adult Solid Tumor
07/23
01/25
DAPPER, NCT03851614: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting
2
90
Canada
Durvalumab, Imfinzi, Olaparib, Lynparza, AZD2281, Cediranib, AZD2171
University Health Network, Toronto, AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
01/25
01/25
DOSa, NCT04668300: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Recruiting
2
75
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Oleclumab, Anti-CD73 Monoclonal Antibody MEDI9447, MEDI9447
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma, Recurrent Angiosarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Osteosarcoma, Refractory Dedifferentiated Liposarcoma, Refractory Osteosarcoma
06/24
06/24
NCT02815995: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Completed
2
56
US
Durvalumab, Tremelimumab
M.D. Anderson Cancer Center, MedImmune LLC
Advanced and/or Metastatic Sarcoma
06/24
06/24
NCT05253131: Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Not yet recruiting
2
41
US
Selumetinib, BI, Durvalumab
University of Alabama at Birmingham, United States Department of Defense
MPNST, NF1, Sarcoma
12/29
12/30
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT02643303: A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Completed
1/2
58
US
Durvalumab, MEDI4736, Imfinzi®, Tremelimumab, Poly-ICLC, Hiltonol®
Ludwig Institute for Cancer Research, MedImmune LLC, Cancer Research Institute, New York City
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
02/22
02/22
NCT03802071: A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma

Active, not recruiting
1/2
44
RoW
Durvalumab+doxorubicin cobination
Yonsei University
Sarcoma
08/22
08/22
NCT05187338: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Recruiting
1/2
100
RoW
ipilimumab +pembrolizumab +durvalumab
Second Affiliated Hospital of Guangzhou Medical University
Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer, Sarcoma
10/29
10/35
NEXIS, NCT03116529: Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

Active, not recruiting
1/2
22
US
Combination Radiation, Immunotherapy, Surgery
University of Maryland, Baltimore, AstraZeneca, University of Arizona, West Penn Allegheny Health System
Soft Tissue Sarcoma
06/32
06/37

Download Options